References in periodicals archive ?
Bu amacla 90Y ibritumomab tiuxetan "Zevalin" ve [sup.13]1I tositumomab "Bexxar" kullanilmaktadir.
Tositumomab. This radioimmunopharmaceutical was introduced by the FDA in 2003.
Illidge, "Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis," Clinical Cancer Research, vol.
Another novel yet effective treatment is radio immunotherapy (RIT) which allows delivery of radiation to lymphoma cells using radioimmunoconjugates ([131]I- tositumomab and [90]Y-ibritutomomab tiuxetan have been approved till now) that target the CD20 antigen and are being used in the setting of recurrent follicular lymphoma setting.
(11) Currently, 2 radiolabelled antibodies are available for treatment of follicular non-Hodgkin's lymphoma, Y-90 ibritumomab tiuxetan (Zevalin) and I-131 tositumomab (Bexxar).
CD 20 ** Bexxar, [27] tositumomab (GlaxoSmithKine) CD 25 ** Ontak, [28] denileukin diftitox (Marathon Biopharmaceuticals Inc.
The antineoplastic agents are alemtuzumab (Campath), bevacizumab (Avastin), cetuximab (Erbitux), gemtuzumab ozogamicin (Mylotarg), ibritumomab tiuxetan (Zevalin), panitumumab (Vectibix), tositumomab and iodine 131 (Bexxar), and trastuzumab (Herceptin).
Marketed antibody drugs and advanced candidates are often directed to the same target and there are apparently four TNF[alpha] antagonists (infliximab, adalimumab, golimumab, certolizumab) in addition to the Fc fusion protein etanercept, five antibodies targeting the B cell receptor CD20 (rituximab, ibritumomab, tositumomab, ofatumumab, ocrelizumab), five to the EGF receptor EGFR (cetuximab, panitumumab, matuzumab, nimotuzumab, zalatumumab), and three to VEGF / VEGFR signalling (bevacizumab, ranibizumab, CDP-791) in addition to the Fc fusion VEGF-Trap.
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911.
tositumomab; monoclonal antibody follicular or transformed non-
In one study, the combined use of radioimmunotherapy with the anti-CD20 monoclonal antibody tositumomab and autologous hematopoietic stem cell transplantation was shown to be beneficial in adults aged 60 and over with high-risk relapsed or refractory B-cell lymphoma, Dr.
Food and Drug Administration (FDA) has requested modifications to the Biologics License Application (BLA) for Bexxar(TM) (tositumomab, iodine I 131 tositumomab) submitted for marketing approval for the treatment of relapsed or refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphoma.